Daratumumab in post-transplantation pure red cell aplasia in adults

Abstract

Post-transplant pure red cell aplasia (PRCA) is a rare complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with ABO incompatibility. In most cases, this condition resolves without any treatment. However, in some patients, PRCA can persist for a long time, worsening the quality of life and somatic status. There is currently no consensus on the treatment of PRCA: previously used therapeutic options have limited application in the post-transplant period and low pathogenetic validity. In this article, we present a series of clinical cases of PRCA treatment with daratumumab, a monoclonal IgG1k anti-CD38 antibody.